Chardan Capital Markets analyst Geulah Livshits downgraded Editas Medicine (NASDAQ: EDIT) from Buy to Neutral.The analyst comments "On 12 December ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE